CCG-203971
CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. This compound also inhibits PC-3 cell migration (IC50: 4.2 μM), as determined by a scratch wound assay. CCG-203971 causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days.
Product Specifications
CAS Number
1443437-74-8
Product Name Alternative
CCG-203971 | CCG 203971
Purity
>98% (HPLC)
Solubility
DMSO : ≥ 155 mg/mL 379.08 mM; H2O : < 0.1 mg/mL
Smiles
O=C (C1CN (C (C2=CC=CC (C3=CC=CO3) =C2) =O) CCC1) NC4=CC=C (Cl) C=C4
Molecular Formula
C23H21ClN2O3
Molecular Weight
408.88
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
N- (4-chlorophenyl) -1-[3- (furan-2-yl) benzoyl]piperidine-3-carboxamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human adenovirus B serotype 7 Uncharacterized 20.6 kDa early protein
Recombinant Human adenovirus B serotype 7 Uncharacterized 20.6 kDa early protein